Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 807

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 807
---
 subject to various performance conditions and funding risk where the financial conditions of the NIH may change from time to time. The Company recognizes the grant only to the extent there is reasonable assurance the grant will be funded to the Company.

F-55

Kintara Therapeutics, Inc. Notes to Condensed Consolidated Interim Financial Statements (Unaudited) December 31, 2023 (expressed in US dollars and in thousands, except par value and per share amounts, unless otherwise noted)

| 5 | Property and equipment, net |

| Balance, June 30, 2023     |     | $(thousands) | 709 |   |
|:---------------------------|:----|:-------------|----:|:--|
| Additions                  |     |              |  20 |   |
| Depreciation               |     |              | (30 | ) |
| Balance, December 31, 2023 |     |              | 699 |   |

At December 31, 2023, the total capitalized cost of property and equipment was $ 879(June 30, 2023 - $ 859), of which $ 699is not in use. The Company has recognized $ 30in depreciation expense, respectively, for each of the six months ended December 31, 2023, and 2022, on equipment in use.

| 6 | Related party transactions |

Valent Technologies, LLC Agreements

On November 20, 2023, Dr. Brown was terminated from his position as the Company’s Chief Scientific Officer as a result of cost-cutting measures adopted by the Company; he remains a consultant to the Company. Dr. Brown is a principal of Valent Technologies, LLC (“Valent”) and as a result Valent is a related party to the Company.

On September 12, 2010, the Company entered into a Patent Assignment Agreement (the “Valent Assignment Agreement”) with Valent pursuant to which Valent transferred to the Company all its right, title and interest in, and to, the patents for VAL-083owned by Valent. The Company now owns all rights and title to VAL-083and is responsible for further development and commercialization. In accordance with the terms of the Valent Assignment Agreement, Valent is entitled to receive a future royalty on all revenues derived from the development and commercialization of VAL-083.In the event that the Company terminates the agreement, the Company may be entitled to receive royalties from Valent’s subsequent development of VAL-083depending